Literature DB >> 15549305

Allogeneic stem cell transplantation for the treatment of diseases associated with a deficiency in bone marrow products.

Reuven Or1, Memet Aker, Michael Yechiel Shapira, Igor Resnick, Menachem Bitan, Simcha Samuel, Shimon Slavin.   

Abstract

Our understanding of the pathophysiology of hematopoietic failure associated syndromes led to the developmental of potentially curative procedures for the treatment of many diseases including Severe aplastic anemia, Fanconi's anemia, Primary immunodeficiency, Osteopetrosis, and Metabolic diseases. Although the number of patients that were transplanted for bone marrow deficiency diseases is relatively low as compared to patients with hematological malignancies, the impact on the knowledge of hematopoiesis and transplantation biology is tremendous. Moreover, the patient's average young age suffering from these diseases further encourage searching for curative approaches. Lucking a fully MHC matched donor, remained a significant obstacle in stem cell transplantation for non-malignant hematological disorders. Lessons from attempts to cure aplasic anemia with bone marrow transplantation guided us to the improvement of pretransplant conditioning regimens and prevention of graft versus host reactions after transplantation. Furthermore, in recent years optimization of disease specific protocol have been successfully designed and clinically applied.

Entities:  

Mesh:

Year:  2004        PMID: 15549305     DOI: 10.1007/s00281-004-0169-z

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  55 in total

1.  Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts.

Authors:  R Storb; J E Sanders; M Pepe; C Anasetti; F R Appelbaum; C D Buckner; H J Deeg; K Doney; J Hansen; P Martin
Journal:  Blood       Date:  1991-08-15       Impact factor: 22.113

Review 2.  Molecular biology of Fanconi anemia: implications for diagnosis and therapy.

Authors:  A D D'Andrea; M Grompe
Journal:  Blood       Date:  1997-09-01       Impact factor: 22.113

3.  Marrow transplantation for severe aplastic anemia. Long-term outcome in fifty "untransfused" patients.

Authors:  C Anasetti; K C Doney; R Storb; J D Meyers; V T Farewell; C D Buckner; F R Appelbaum; K M Sullivan; R A Clift; H J Deeg
Journal:  Ann Intern Med       Date:  1986-04       Impact factor: 25.391

4.  Long-term outcome after marrow transplantation for severe aplastic anemia.

Authors:  H J Deeg; W Leisenring; R Storb; J Nims; M E Flowers; R P Witherspoon; J Sanders; K M Sullivan
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

Review 5.  The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome.

Authors:  W Krivit; L A Lockman; P A Watkins; J Hirsch; E G Shapiro
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

6.  Treatment with marrow transplantation or immunosuppression of childhood acquired severe aplastic anemia: a report from the EBMT SAA Working Party.

Authors:  A Locasciulli; L van't Veer; A Bacigalupo; J Hows; M T Van Lint; E Gluckman; C Nissen; S McCann; J Vossen; A Schrezenmeier
Journal:  Bone Marrow Transplant       Date:  1990-09       Impact factor: 5.483

7.  Chorioretinal degeneration in infantile malignant osteopetrosis.

Authors:  J B Ruben; R J Morris; G F Judisch
Journal:  Am J Ophthalmol       Date:  1990-07-15       Impact factor: 5.258

8.  Hematopoietic stem cell transplantation for infantile osteopetrosis.

Authors:  M Eapen; S M Davies; N K Ramsay; P J Orchard
Journal:  Bone Marrow Transplant       Date:  1998-11       Impact factor: 5.483

9.  Recombinant human interferon gamma therapy for osteopetrosis.

Authors:  L L Key; W L Ries; R M Rodriguiz; H C Hatcher
Journal:  J Pediatr       Date:  1992-07       Impact factor: 4.406

10.  Allogeneic bone marrow transplantation for fucosidosis.

Authors:  A Vellodi; H Cragg; B Winchester; E Young; J Young; C J Downie; R D Hoare; R Stocks; G K Banerjee
Journal:  Bone Marrow Transplant       Date:  1995-01       Impact factor: 5.483

View more
  3 in total

1.  Mechanisms of alloimmunization and subsequent bone marrow transplantation rejection induced by platelet transfusion in a murine model.

Authors:  S R Patel; N H Smith; L Kapp; J C Zimring
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

Review 2.  Transfusion-induced bone marrow transplant rejection due to minor histocompatibility antigens.

Authors:  Seema R Patel; James C Zimring
Journal:  Transfus Med Rev       Date:  2013-10-03

3.  Transfusion of minor histocompatibility antigen-mismatched platelets induces rejection of bone marrow transplants in mice.

Authors:  Seema R Patel; Chantel M Cadwell; Arielle Medford; James C Zimring
Journal:  J Clin Invest       Date:  2009-08-10       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.